LifeMD, Inc. (LFMD) Stock Analysis and Metrics

LifeMD

NASDAQ: LFMD

$3.71 ▼ -0.15 (-4.01%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap180.96 Mn

P/E12.39

P/S1.53

Div. Yield0.02

ROIC (Qtr)0.00

Revenue Growth (1y) (Qtr)29.03

Add ratio to table…

About

LifeMD, Inc. is a patient centric direct to patient healthcare company that provides virtual medical care and pharmacy services through a vertically integrated platform. The company combines proprietary technology affiliated clinical services pharmacy infrastructure and AI enabled operational systems to deliver longitudinal care at scale. It serves patients across primary care men's and women's health hormone health weight management insomnia dermatology and cardiology. It offers virtual clinical services and prescription and over the counter treatments when medically appropriate. As of December 31 2025 LifeMD served approximately 328000 active patient subscribers. Since inception the company has served approximately 1387000 patients and customers.

LifeMD generates revenue primarily from recurring subscription fees which account for about ninety five percent of total revenue. Its virtual primary care services are offered through a subscription model that provides patients with ongoing access to affiliated providers prescription fulfillment and care management. Additional revenue streams include pharmacy sales from its wholly owned affiliated commercial pharmacy and fees from business to business telehealth partnerships with healthcare product companies. Telehealth revenue increased twenty five percent for the year ended December 31 2025 compared with the prior year. The company also earns income from prescription sales over the counter products and from collaborations such as the Medifast arrangement that provided upfront payments and equity considerations.

The company operates through the following segments: LifeMD brand Rex MD ShapiroMD and B2B Telehealth Partnerships.

• LifeMD brand is the flagship virtual primary care and specialty platform that offers patients access to affiliated providers for urgent and chronic care needs. It provides on demand consultations prescription medications diagnostics imaging wellness coaching and integration with in home tools. The brand addresses high growth underserved verticals through defined specialty care programs including weight management women's health and behavioral health. It has served over 679000 customers and patients to date.

• Rex MD is the men's telehealth platform focused on conditions that are often underdiagnosed or undertreated due to stigma inconvenience or limited access to specialized providers. It delivers virtual diagnosis treatment and prescription medications for men's health conditions such as erectile dysfunction premature ejaculation hair loss insomnia weight loss and performance anxiety. Services are provided through affiliated licensed medical providers and prescription therapies are dispensed through the wholly owned pharmacy or partner pharmacies as clinically appropriate. Rex MD has served approximately 691000 customers and patients since launch.

• ShapiroMD is a legacy brand that offers virtual medical treatment prescription medications patented doctor formulated over the counter products topical compounded medications and FDA approved medical devices treating male and female hair loss. It has served approximately 261000 customers and patients to date. ShapiroMD is a leading destination for hair loss treatment across the United States.

• B2B Telehealth Partnerships involve collaborations with healthcare product companies to deliver digital patient awareness access adherence and compliance solutions. Notable partnerships include an integration with LillyDirect for streamlined access to Zepbound a connection with CenterWell Pharmacy for fulfillment of Wegovy and Ozempic a collaboration with Withings for in home health monitoring devices a partnership with Ash Wellness for at home laboratory testing an arrangement with Medifast for a clinically supported weight management program and an agreement with ASCEND Therapeutics for women's health services. These partnerships generate fees and support the expansion of the LifeMD platform.

LifeMD holds a strong position in the competitive telehealth and virtual care industry. Numerous online brands compete with the company in virtual primary care weight loss men's and women's health and hair loss markets. Traditional mass merchandisers drug store chains and independent pharmacies also represent competition. The company's competitive advantages include an affiliated fifty state medical group that is dedicated to patient care and staffed largely with full time providers. Its industry leading telehealth technology platform supports the delivery of complex primary care and the management of a broad range of chronic conditions. LifeMD owns a wholly owned affiliated commercial pharmacy and fulfillment center that enables personalized prescription experiences. Flexible patient payment options are available including increasing commercial and Medicare insurance capabilities for care pharmacy and medical benefits. An in house patient service center provides dedicated support for patient care and customer relationship management. Robust CRM patient acquisition and retention capabilities are powered by real time data analytics and AI enabled tools. A compliance first mindset ensures that patients have access to their clinical data through a full scale electronic medical record system while the company adheres to strict regulatory standards. Established collaborations and platform integrations with leading GLP 1 manufacturers such as Novo Nordisk and Lilly create streamlined access pathways prescription fulfillment integrations and enhanced support for patients prescribed branded obesity and diabetes therapies.

The company serves men and women who seek virtual healthcare and pharmacy services for a wide range of conditions including primary care men's and women's health hormone health weight management insomnia dermatology and cardiology. Its customers are individual patients who subscribe to its services or use its pharmacy on a pay per visit basis. No single patient accounts for more than ten percent of net sales.

Investment Thesis

▲ Bull case

LifeMD Inc.'s strategic pivot toward insurance-supported GLP-1 programs is creating a structural advantage that the market is significantly underestimating, with the company now covering approximately 230 million lives and achieving a 50% reduction in customer acquisition costs for insured patients compared to self-pay counterparts, while simultaneously improving retention by at least 10% as noted in the Q&A session, which suggests a durable shift toward higher-LTV patients that will drive predictable, recurring revenue streams less susceptible to marketing spend volatility and competitive pricing pressures in the direct-to-consumer weight management space, particularly as the Medicare GLP-1 Bridge program launches July 1 and expands access to an underserved demographic with high chronic disease burden and strong payer incentives for cost-effective obesity interventions.
The integration of LifeMD Inc.'s 503A compounding pharmacy with its AI-driven clinical decision support infrastructure represents a hidden catalyst for margin expansion that management did not fully quantify, enabling personalized prescribing at scale through data-informed formulations tailored to biomarker profiles and treatment response, a capability few telehealth platforms possess due to the rarity of combining national pharmacy licensing, 50-state medical group affiliation, and proprietary AI tools, which positions the company to capture premium pricing for differentiated therapies in Women's Health and Men's Health programs while reducing reliance on third-party suppliers and improving gross margins beyond the current 88% level as fulfillment efficiencies scale and cross-selling opportunities from RexMD's engaged base of 215 thousand active patients materialize into higher platform utilization and retention.
LifeMD Inc.'s Women's Health program is exhibiting exponential early traction with subscriber growth exceeding 7x from the Q4 base and on-therapy retention tracking above 80%, signaling a durable product-market fit in a massively underserved market where tens of millions of women face menopause-related symptoms with limited access to coordinated, evidence-based care, and the planned launch of seven new compounded pharmacy products focused on hormone and bone health will deepen clinical integration and create switching costs by aligning pharmacy capabilities directly with longitudinal care protocols, transforming the initiative from a growth driver into a defensible, high-margin specialty vertical that could rival weight management in scale and profitability as retention improves and cross-sell opportunities with existing GLP-1 and Men's Health patients increase lifetime value beyond current models.
The company's reacceleration of enterprise and pharmaceutical partnership models—previously deprioritized in favor of direct-to-consumer acquisition—represents an underappreciated upside vector where large partners offer LifeMD Inc.'s services to their membership bases, creating a low-CAC, high-retention channel that mirrors the economics of insurance-supported programs but with potentially better margins due to reduced revenue sharing and greater control over patient experience, a shift that could meaningfully contribute to the back-half EBITDA ramp as marketing spend normalizes and the sales force shifts from paid media to partnership development, leveraging the platform's proven ability to deliver quality care and products at scale to unlock recurring B2B revenue streams with longer contract durations and lower churn than volatile consumer acquisition campaigns.

LifeMD Inc.'s strategic pivot toward insurance-supported GLP-1 programs is creating a structural advantage that the market is significantly underestimating, with the company now covering approximately 230 million lives and achieving a 50% reduction in customer acquisition costs for insured patients compared to self-pay counterparts, while simultaneously improving retention by at least 10% as noted in the Q&A session, which suggests a durable shift toward higher-LTV patients that will drive predictable, recurring revenue streams less susceptible to marketing spend volatility and competitive pricing pressures in the direct-to-consumer weight management space, particularly as the Medicare GLP-1 Bridge program launches July 1 and expands access to an underserved demographic with high chronic disease burden and strong payer incentives for cost-effective obesity interventions.
The integration of LifeMD Inc.'s 503A compounding pharmacy with its AI-driven clinical decision support infrastructure represents a hidden catalyst for margin expansion that management did not fully quantify, enabling personalized prescribing at scale through data-informed formulations tailored to biomarker profiles and treatment response, a capability few telehealth platforms possess due to the rarity of combining national pharmacy licensing, 50-state medical group affiliation, and proprietary AI tools, which positions the company to capture premium pricing for differentiated therapies in Women's Health and Men's Health programs while reducing reliance on third-party suppliers and improving gross margins beyond the current 88% level as fulfillment efficiencies scale and cross-selling opportunities from RexMD's engaged base of 215 thousand active patients materialize into higher platform utilization and retention.
LifeMD Inc.'s Women's Health program is exhibiting exponential early traction with subscriber growth exceeding 7x from the Q4 base and on-therapy retention tracking above 80%, signaling a durable product-market fit in a massively underserved market where tens of millions of women face menopause-related symptoms with limited access to coordinated, evidence-based care, and the planned launch of seven new compounded pharmacy products focused on hormone and bone health will deepen clinical integration and create switching costs by aligning pharmacy capabilities directly with longitudinal care protocols, transforming the initiative from a growth driver into a defensible, high-margin specialty vertical that could rival weight management in scale and profitability as retention improves and cross-sell opportunities with existing GLP-1 and Men's Health patients increase lifetime value beyond current models.
The company's reacceleration of enterprise and pharmaceutical partnership models—previously deprioritized in favor of direct-to-consumer acquisition—represents an underappreciated upside vector where large partners offer LifeMD Inc.'s services to their membership bases, creating a low-CAC, high-retention channel that mirrors the economics of insurance-supported programs but with potentially better margins due to reduced revenue sharing and greater control over patient experience, a shift that could meaningfully contribute to the back-half EBITDA ramp as marketing spend normalizes and the sales force shifts from paid media to partnership development, leveraging the platform's proven ability to deliver quality care and products at scale to unlock recurring B2B revenue streams with longer contract durations and lower churn than volatile consumer acquisition campaigns.

▼ Bear case

LifeMD Inc.'s reported gross margin expansion to 88% in Q1 may be overstated and unsustainable, as the improvement was driven primarily by temporary reductions in shipping and fulfillment costs tied to the initial scaling of in-house pharmacy operations, which are now facing capacity constraints at the 22.5 thousand square foot facility processing only 20 thousand prescriptions monthly despite significant advertised headroom, and any further margin gains will require difficult trade-offs between investing in pharmacy automation versus maintaining flexibility for compounding innovation, while concurrent pressures from branded GLP-1 pricing negotiations with Novo Nordisk and Eli Lilly—evidenced by management's inability to disclose unit economics details due to NDAs—suggest that reimbursement rates and rebates could compress pharmacy spreads faster than anticipated, undermining the margin expansion thesis as the company shifts fully away from higher-margin compounded GLP-1s to lower-margin branded alternatives under its stated strategic pivot.
The apparent strength in insurance-supported programs, characterized by 50% lower CAC and improved retention, may be misleading due to adverse selection risks where patients accessing GLP-1 therapies through insurance are inherently sicker and more complex to manage, requiring greater clinical resources and follow-up that are not yet reflected in current provider capacity metrics, and as the company scales to 230 million covered lives, the promised CAC efficiencies could reverse if insurers begin imposing stricter prior authorization requirements or step-therapy protocols in response to rising utilization, particularly given that LifeMD Inc. has not built the Medicare GLP-1 Bridge program into its financial model despite expressing optimism, indicating a lack of concrete contractual assurances on reimbursement durability or patient volume predictability that would be necessary to support the assumed EBITDA ramp in the second half of the year.
LifeMD Inc.'s reliance on AI to drive provider capacity increases and operating leverage remains unproven at scale, with no disclosed metrics on actual time savings per provider, reduction in administrative burden, or improvements in clinical throughput, and the claim that AI will enable more personalized care without adding headcount contradicts the concurrent 34% year-over-year increase in selling and marketing expenses driven by front-loaded patient acquisition spend, which suggests that the platform's current growth engine is still heavily dependent on costly customer acquisition rather than organic retention or efficiency gains, raising concerns that the AI narrative is being used to justify future profitability without sufficient near-term evidence of productivity gains, especially as the company expands into complex longitudinal care programs like Women's Health that demand higher provider involvement per patient rather than less.
The company's guidance for annualized run-rate revenue exceeding $250 million and adjusted EBITDA above $25 million by Q4 2026 appears aggressive given the sequential revenue decline from Q1 2025 to Q1 2026 despite subscriber growth, the ongoing migration from compounded to branded GLP-1s which management admits yields lower unit economics, and the softness in Q2 revenue guidance ($47–$50 million) relative to Q1 ($50.2 million), which management attributes to intentional pricing adjustments in Women's Health and insurance billing optimization—factors that could persistently suppress ARPU even as subscriber counts rise, creating a scenario where top-line growth is achieved through volume alone while monetization per user stagnates or declines, making it difficult to reach the implied EBITDA margins necessary to hit profitability targets without unsustainable cuts to sales and marketing or unexpected upside from unquantified initiatives like pharmaceutical collaborations or employer programs that remain in early stages and lack disclosed timelines or financial contributions.

LifeMD Inc.'s reported gross margin expansion to 88% in Q1 may be overstated and unsustainable, as the improvement was driven primarily by temporary reductions in shipping and fulfillment costs tied to the initial scaling of in-house pharmacy operations, which are now facing capacity constraints at the 22.5 thousand square foot facility processing only 20 thousand prescriptions monthly despite significant advertised headroom, and any further margin gains will require difficult trade-offs between investing in pharmacy automation versus maintaining flexibility for compounding innovation, while concurrent pressures from branded GLP-1 pricing negotiations with Novo Nordisk and Eli Lilly—evidenced by management's inability to disclose unit economics details due to NDAs—suggest that reimbursement rates and rebates could compress pharmacy spreads faster than anticipated, undermining the margin expansion thesis as the company shifts fully away from higher-margin compounded GLP-1s to lower-margin branded alternatives under its stated strategic pivot.
The apparent strength in insurance-supported programs, characterized by 50% lower CAC and improved retention, may be misleading due to adverse selection risks where patients accessing GLP-1 therapies through insurance are inherently sicker and more complex to manage, requiring greater clinical resources and follow-up that are not yet reflected in current provider capacity metrics, and as the company scales to 230 million covered lives, the promised CAC efficiencies could reverse if insurers begin imposing stricter prior authorization requirements or step-therapy protocols in response to rising utilization, particularly given that LifeMD Inc. has not built the Medicare GLP-1 Bridge program into its financial model despite expressing optimism, indicating a lack of concrete contractual assurances on reimbursement durability or patient volume predictability that would be necessary to support the assumed EBITDA ramp in the second half of the year.
LifeMD Inc.'s reliance on AI to drive provider capacity increases and operating leverage remains unproven at scale, with no disclosed metrics on actual time savings per provider, reduction in administrative burden, or improvements in clinical throughput, and the claim that AI will enable more personalized care without adding headcount contradicts the concurrent 34% year-over-year increase in selling and marketing expenses driven by front-loaded patient acquisition spend, which suggests that the platform's current growth engine is still heavily dependent on costly customer acquisition rather than organic retention or efficiency gains, raising concerns that the AI narrative is being used to justify future profitability without sufficient near-term evidence of productivity gains, especially as the company expands into complex longitudinal care programs like Women's Health that demand higher provider involvement per patient rather than less.
The company's guidance for annualized run-rate revenue exceeding $250 million and adjusted EBITDA above $25 million by Q4 2026 appears aggressive given the sequential revenue decline from Q1 2025 to Q1 2026 despite subscriber growth, the ongoing migration from compounded to branded GLP-1s which management admits yields lower unit economics, and the softness in Q2 revenue guidance ($47–$50 million) relative to Q1 ($50.2 million), which management attributes to intentional pricing adjustments in Women's Health and insurance billing optimization—factors that could persistently suppress ARPU even as subscriber counts rise, creating a scenario where top-line growth is achieved through volume alone while monetization per user stagnates or declines, making it difficult to reach the implied EBITDA margins necessary to hit profitability targets without unsustainable cuts to sales and marketing or unexpected upside from unquantified initiatives like pharmaceutical collaborations or employer programs that remain in early stages and lack disclosed timelines or financial contributions.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Health Information Services

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	VEEV	Veeva Systems Inc	29.34 Bn	31.16	8.84	-
2	BTSG	BrightSpring Health Services, Inc.	13.49 Bn	46.18	0.99	2.50 Bn
3	HQY	Healthequity, Inc.	7.96 Bn	34.51	5.95	0.94 Bn
4	TXG	10x Genomics, Inc.	6.17 Bn	-272.14	9.65	-
5	HNGE	Hinge Health, Inc.	6.02 Bn	-11.77	9.31	-
6	MMED	MiniMed Group, Inc.	4.19 Bn	-8.88	1.38	-
7	WAY	Waystar Holding Corp.	4.14 Bn	32.80	3.58	1.47 Bn
8	DOCS	Doximity, Inc.	3.82 Bn	19.51	5.93	-

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password